Dr. Michael Gorin, MD

• Urology

• Prostate Oncology

• Endourology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Endourology & Minimally Invasive Surgery, Johns Hopkins University School Of Medicine

  Fellowship Hospital, 2019

• Johns Hopkins School Of Medicine

  Residency Hospital, 2017

• Urology, Johns Hopkins University School Of Medicine

  Residency Hospital, 2017

• General Surgery, Johns Hopkins University School Of Medicine

  Internship Hospital, 2012

• Johns Hopkins School Of Medicine

  Internship Hospital, 2012

• University Of Miami Miller School Of Medicine

  Medical School, 2011

• University Of Michigan, Ann Arbor

  Undergraduate School, 2007

• University Of Michigan

  Undergraduate School, 2007

• Deep learning and radiomics framework for PSMA-RADS classification of prostate cancer on PSMA PET, 2022-12-29

• Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted18F-DCFPyL PET/CT, 2015-08-19

• Standardized Nomenclature and Surveillance Methodologies After Focal Therapy and Partial Gland Ablation for Localized Prostate Cancer: An International Multidisciplinary Consensus, 2020-06-10

• Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer The ORIOLE Phase 2 Randomized Clinical Trial Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer, 2020-03-26

• Prostate Specific Antigen and Prostate Specific Antigen Doubling Time Predict Findings on18F-DCFPyL Positron Emission Tomography/Computerized Tomography in Patients with Biochemically Recurrent Prostate Cancer, 2020-04-06

• Pre-clinical development of a bi-functional cancer cell homing, PKCe inhibitory peptide for the treatment of head and neck cancer, 2009-06-30

• A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS), 2020-06-01

• Imaging of carbonic anhydrase IX with an111In-labeled dual-motif inhibitor, 2015-09-16

• Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell Carcinoma, 2021-05-26

• 18F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging, 2020-01-01

• Step-adjusted Tree-based Reinforcement Learning (SAT-Learning) for Evaluating Nested Dynamic Treatment Regimes using Test-and-Treat Observational Data, 2021-09-07

• Extent of Renal Vein Invasion Influences Prognosis in Patients with Renal Cell Carcinoma, 2015-11-14

• A simple selection-free method for detecting disseminated tumor cells (DTCs) in murine bone marrow, 2016-09-13

• Development of an Automated and Sensitive Microfluidic Device for Capturing and Characterizing Circulating Tumor Cells (CTCs) from Clinical Blood Samples, 2016-01-25

• Protein kinase Ce: an oncogene and emerging tumor biomarker, 2009-02-19

• Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations, 2016-10-11

• Process validation, cGMP production, dosimetry, and toxicity studies of the CAIX imaging agent [111In]XYIMSR-01 for phase I regulatory approval, 2021-03-04

• Correlation of99mTc-sestamibi uptake in renal masses with mitochondrial content and multi-drug resistance pump expression, 2017-10-02

• PSMA-Targeted18F-DCFPyL PET/CT Imaging of Clear Cell Renal Cell Carcinoma: Results from a Rapid Autopsy, 2016-06-28

• A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE), 2017-06-29

• Circulating Tumor DNA as a Marker of Therapeutic Response in Patients With Renal Cell Carcinoma: A Pilot Study, 2016-03-24

• Low Levels of PSMA Expression Limit the Utility of18F-DCFPyL PET/CT for Imaging Urothelial Carcinoma, 2017-10-24

• Detection of Biochemically Recurrent Prostate Cancer with [18F]DCFPyL PET/CT: An Updated Systematic Review and Meta-Analysis with a Focus on Correlations with Serum Prostate-Specific Antigen Parameters, 2023-08-15

• Data on the quality and methods of studies reporting healthcare costs of post-prostate biopsy sepsis, 2019-07-25

• Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Intrapatient and Interpatient Variability of Normal Organ Uptake, 2021-02-26

• Stereotactic Ablative Radiotherapy for the Treatment of Clinically Localized Renal Cell Carcinoma, 2015-11-11

• Technical challenges in the isolation and analysis of circulating tumor cells, 2016-08-10

• Recent Updates on Molecular Imaging Reporting and Data Systems (MI-RADS) for Theranostic Radiotracers-Navigating Pitfalls of SSTR- and PSMA-Targeted PET/CT, 2019-07-19

• Characterization of indeterminate renal masses with molecular imaging: how do we turn potential into reality?, 2017-04-12

• PSMA-Based Detection of Prostate Cancer Bone Lesions with18F-DCFPyL PET/CT: A Sensitive Alternative to99mTc-MDP Bone Scan and Na18F PET/CT?, 2015-09-30

• Comparative Effectiveness of Management Options for Patients with Small Renal Masses: A Prospective Cohort Study, 2018-08-09

• Diagnostic Performance of18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase 3, Multicenter Study, 2021-02-23

• A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer, 2021-04-08

• Inverted Nutcracker Syndrome: A Case of Persistent Hematuria and Pain in the Presence of a Left-Sided Inferior Vena Cava, 2011-05-05

• Uptake of18F-DCFPyL in Paget's Disease of Bone, an Important Potential Pitfall in Clinical Interpretation of PSMA PET Studies, 2016-01-06

• Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted18F-DCFPyL in peripheral ganglia, 2017-08-22

• PSMA-RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMA-targeted PET Imaging Studies, 2017-11-11

• A surface tension magnetophoretic device for rare cell isolation and characterization, 2017-01-05

• Partial Nephrectomy for the Treatment of Translocation Renal Cell Carcinoma, 2014-12-20

• Hereditary spherocytosis presenting as diffuse bone marrow activation and splenomegaly on PSMA-targeted18F-DCFPyL PET/CT, 2019-01-03

• Preoperative Predictors of Malignancy and Unfavorable Pathology for Clinical T1a Tumors Treated with Partial Nephrectomy: A Multi-Institutional Analysis, 2014-12-11

• Definitive and Sustained Increase in Prostate Cancer Metastases in the United States, 2019-09-12

• Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake, 2020-12-23

• Computed Tomography Appearance of Renal Hybrid Oncocytic/Chromophobe Tumors, 2016-06-02

• [64Cu]XYIMSR-06: A dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma, 2016-07-14

• "TREXIT 2020”: why the time to abandon transrectal prostate biopsy starts now, 2020-01-13

• Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications, 2018-08-14

• Characterization of Applicant Preference Signals, Invitations for Interviews, and Inclusion on Match Lists for Residency Positions in Urology Preference Signals and Invitations for Interviews for Residency Positions in Urology, 2023-01-20